Ra Capital Management, L.p. Buys BELLUS Health Inc, Mirati Therapeutics Inc, Pardes Biosciences Inc, Sells Atea Pharmaceuticals Inc, TG Therapeutics Inc, Verve Therapeutics Inc

• New Purchases: BLU, MRTX, PRDS, LIAN, RLMD, XLO, PYXS, RLAY, KDNY, IOBT, CMPX,
• Added Positions: ASND, EYPT, IMGN, OTIC, PCVX, CLDX, MGNX, PNT,
• Reduced Positions: TGTX, VERV, ADGI, GHRS, ORTX, LRMR, SCPH,
• Sold Out: AVIR, CTMX, FSII, AADI, OCUL, HLXA, CCXI, RPHM, VRDN,

For the details of RA CAPITAL MANAGEMENT, L.P.'s stock buys and sells, go to https://www.gurufocus.com/guru/ra+capital+management%2C+l.p./current-portfolio/portfolio

1. Ascendis Pharma A/S (ASND) - 7,567,900 shares, 17.95% of the total portfolio. Shares added by 2.44%
2. Novavax Inc (NVAX) - 2,097,794 shares, 5.29% of the total portfolio.
3. ITeos Therapeutics Inc (ITOS) - 4,417,259 shares, 3.63% of the total portfolio.
4. Travere Therapeutics Inc (TVTX) - 5,614,428 shares, 3.07% of the total portfolio.
5. Janux Therapeutics Inc (JANX) - 8,670,644 shares, 3.02% of the total portfolio.

Ra Capital Management, L.p. initiated holding in BELLUS Health Inc. The purchase prices were between $5.26 and $8.3, with an estimated average price of $6.65. The stock is now traded at around $7.105000. The impact to a portfolio due to this purchase was 1.45%. The holding were 10,230,274 shares as of 2021-12-31.

Ra Capital Management, L.p. initiated holding in Mirati Therapeutics Inc. The purchase prices were between $132.01 and $190.29, with an estimated average price of $154.69. The stock is now traded at around $93.615000. The impact to a portfolio due to this purchase was 0.99%. The holding were 381,046 shares as of 2021-12-31.

Ra Capital Management, L.p. initiated holding in Pardes Biosciences Inc. The purchase prices were between $10.62 and $17.02, with an estimated average price of $13.8. The stock is now traded at around $8.926500. The impact to a portfolio due to this purchase was 0.9%. The holding were 3,127,038 shares as of 2021-12-31.

Ra Capital Management, L.p. initiated holding in LianBio. The purchase prices were between $6.14 and $16.2, with an estimated average price of $11.42. The stock is now traded at around $4.337300. The impact to a portfolio due to this purchase was 0.83%. The holding were 7,655,015 shares as of 2021-12-31.

Ra Capital Management, L.p. initiated holding in Relmada Therapeutics Inc. The purchase prices were between $16.93 and $26.82, with an estimated average price of $22.13. The stock is now traded at around $19.020000. The impact to a portfolio due to this purchase was 0.79%. The holding were 2,000,000 shares as of 2021-12-31.

Ra Capital Management, L.p. initiated holding in Xilio Therapeutics Inc. The purchase prices were between $9.69 and $25.11, with an estimated average price of $17.08. The stock is now traded at around $14.415000. The impact to a portfolio due to this purchase was 0.56%. The holding were 2,002,217 shares as of 2021-12-31.

Ra Capital Management, L.p. added to a holding in EyePoint Pharmaceuticals Inc by 52.48%. The purchase prices were between $10.18 and $18.4, with an estimated average price of $13.54. The stock is now traded at around $9.760000. The impact to a portfolio due to this purchase was 0.25%. The holding were 3,370,506 shares as of 2021-12-31.

Ra Capital Management, L.p. added to a holding in Otonomy Inc by 243.21%. The purchase prices were between $1.69 and $2.31, with an estimated average price of $2.06. The stock is now traded at around $2.098000. The impact to a portfolio due to this purchase was 0.15%. The holding were 5,600,000 shares as of 2021-12-31.

Ra Capital Management, L.p. sold out a holding in Atea Pharmaceuticals Inc. The sale prices were between $7.67 and $44.59, with an estimated average price of $14.96.

Ra Capital Management, L.p. sold out a holding in CytomX Therapeutics Inc. The sale prices were between $3.87 and $7.39, with an estimated average price of $5.86.

Ra Capital Management, L.p. sold out a holding in FS Development Corp II. The sale prices were between $9.8 and $14.97, with an estimated average price of $11.43.

Ra Capital Management, L.p. sold out a holding in Aadi Bioscience Inc. The sale prices were between $19.32 and $29.02, with an estimated average price of $25.03.

Ra Capital Management, L.p. sold out a holding in Ocular Therapeutix Inc. The sale prices were between $6.16 and $12.07, with an estimated average price of $7.7.

Ra Capital Management, L.p. sold out a holding in Helix Acquisition Corp. The sale prices were between $9.86 and $10.15, with an estimated average price of $9.93.